Brainsway Ltd Revenue and Competitors

Jerusalem,

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Brainsway Ltd's estimated annual revenue is currently $44.2M per year.(i)
  • Brainsway Ltd's estimated revenue per employee is $251,000

Employee Data

  • Brainsway Ltd has 176 Employees.(i)
  • Brainsway Ltd grew their employee count by 9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$139.8M68516%$200KN/A
#4
$84.1M0N/A$1.2MN/A
#5
$35.6M14230%N/AN/A
#6
$54.5M21715%N/AN/A
#7
$52.7M16825%$129.6MN/A
#8
$21.8M87-13%N/AN/A
#9
$70M2799%N/AN/A
#10
$60.6M19320%$115.5MN/A
Add Company

BrainsWay is a leading global neuromodulation company with headquarters in Jerusalem and the US. Our patented breakthrough technology has already treated over 10,000 patients, and has helped usher in a new era in brain disorder treatment. A non-invasive, yet highly effective solution for brain disorders, BrainsWay has helped thousands of patients across the world, from the Unites States to Europe to South America, and has the potential to make a difference in the well-being and health of millions of patients worldwide. BrainsWay's technology offers a much needed alternative for millions of patients from a bleak cycle of insufficiently effective treatments and unpleasant side effects. BrainsWay's treatment has FDA approval for treating patients with Major Depressive Disorder*. The technology is safe, with no systemic or long-term side effects, in addition to being highly convenient, requiring only brief daily sessions over a few weeks. In addition to being used to treat depression daily across the world, BrainsWay's technology has been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials performed. BrainsWay technology is based on a patent registered by the U.S. National Institutes of Health (NIH). BrainsWay is dedicated to research and continuously explores treatments for a variety of brain disorders. * The Brainsway Deep TMS System is indicated by the FDA for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. FDA 510(k) No. 122888

keywords:N/A

N/A

Total Funding

176

Number of Employees

$44.2M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Brainsway Ltd News

2022-04-20 - BrainsWay Ltd. (NASDAQ:BWAY) Given Average Rating of “Buy” by ...

Shares of BrainsWay Ltd. (NASDAQ:BWAY – Get Rating) have earned a consensus recommendation of “Buy” from the five research firms that are...

2022-04-20 - $7.45 Million in Sales Expected for BrainsWay Ltd. (NASDAQ:BWAY ...

Wall Street brokerages forecast that BrainsWay Ltd. (NASDAQ:BWAY – Get Rating) will announce $7.45 million in sales for the current quarter,...

2022-04-17 - -$0.09 Earnings Per Share Expected for BrainsWay Ltd. (NASDAQ ...

Wall Street brokerages expect BrainsWay Ltd. (NASDAQ:BWAY – Get Rating) to report ($0.09) earnings per share (EPS) for the current quarter,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$29.4M19126%N/A
#2
$7.5M19615%$140.2M
#3
N/A24017%N/A
#4
$15M280-8%$197.5M
#5
$147.2M4364%N/A